Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
IPO Year:
Exchange: NASDAQ
Website: aytubio.com
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
ARS - AYTU BIOPHARMA, INC (0001385818) (Filer)
DEFA14A - AYTU BIOPHARMA, INC (0001385818) (Filer)
DEF 14A - AYTU BIOPHARMA, INC (0001385818) (Filer)
8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
Cantor Fitzgerald initiated coverage of Aytu BioPharma with a rating of Overweight and set a new price target of $11.00
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 73.06 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $17.993 million which beat the analyst consensus estimate of $17.346 million by 3.73 percent. This is a 20.85 percent decrease over sales of $22.733 million the same period last year.
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million which beat the analyst consensus estimate of $21.75 million by 5.47 percent. This is a 12.73 percent decrease over sales of $26.28 million the same period last year.
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. • CAE (NYSE:CAE) is estimated to report quarterly earnings at $0.18 per share on revenue of $819.57 million. • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.42 per share on revenue of $6.66 billion. • Great Lakes Dredge & Dock (NASDAQ:GLDD) is estimated to report quarterly earnings at $0.10 per share on revenue of $183.47 million. • Louisiana-Pacific (NYSE:LPX) is likely to report quarterly earnings at $0.55 per share on revenue of $619.97 million. • Martin Marietta Materials (NYSE:MLM) is projected to repor
Aytu BioPharma (NASDAQ:AYTU) is set to give its latest quarterly earnings report on Wednesday, 2024-02-14. Here's what investors need to know before the announcement. Analysts estimate that Aytu BioPharma will report an earnings per share (EPS) of $-0.25. Aytu BioPharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Here's a look at Aytu BioPharma's past performance and the resulting price change: Quarter Q1 2024 Q4 2023 Q3
Gainers Telesis Bio (NASDAQ:TBIO) shares increased by 32.5% to $0.53 during Wednesday's after-market session. The company's market cap stands at $15.8 million. Femasys (NASDAQ:FEMY) shares rose 19.28% to $1.09. The market value of their outstanding shares is at $23.5 million. Axcella Health (NASDAQ:AXLA) shares rose 13.1% to $5.18. The company's market cap stands at $15.2 million. Assembly Biosciences (NASDAQ:ASMB) stock increased by 12.96% to $0.73. The market value of their outstanding shares is at $48.0 million. MyMD Pharmaceuticals (NASDAQ:MYMD) stock moved upwards by 9.96% to $0.32. The market value of their outstanding shares is at $14.3 million. Eiger BioPharmaceuticals (NASDAQ:
Shares of Shapeways Holdings, Inc. (NASDAQ:SHPW) tumbled during Wednesday’s session following downbeat results. Shapeways Hldgs posted an adjusted loss of $1.36 per share, versus market expectations for a loss of 95 cents per share. The company’s quarterly sales came in at $8.37 million versus estimates of $8.75 million. Shapeways shares fell 20.8% to $2.36 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares climbed 62.4% to $2.16 after the company reported third-quarter results. Chemomab Therapeutics Ltd. (NASDAQ:CMMB) shares jumped 55% to $0.9497 after the FDA granted CM-101 Fast Track designation for
Gainers Heron Therapeutics (NASDAQ:HRTX) stock moved upwards by 63.0% to $0.88 during Wednesday's regular session. As of 12:31 EST, Heron Therapeutics's stock is trading at a volume of 15.8 million, which is 750.5% of its average full-day volume over the last 100 days. The company's market cap stands at $123.8 million. The company's, Q3 earnings came out yesterday. Kinnate Biopharma (NASDAQ:KNTE) shares increased by 57.32% to $2.47. The current volume of 55.3 million shares is 35889.2% of Kinnate Biopharma's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $116.3 million. As per the press release, Q3 earnings cam
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(1.48) per share. This is a 23.33 percent decrease over losses of $(1.20) per share from the same period last year. The company reported quarterly sales of $22.10 million which missed the analyst consensus estimate of $27.73 million by 20.31 percent. This is a 20.09 percent decrease over sales of $27.66 million the same period last year.
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million. • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its third quarter. • Argo Blockchain (NASDAQ:ARBK) is estimated to report quarterly loss at $0.12 per share on revenue of $13.28 million. • SuperCom (NASDAQ:SPCB) is estimated to report quarterly earnings at $0.00 per share on revenue of $4.60 million. • Moving iMage Technologies (AMEX:MITQ) is projected to report earnings for its first quarter. • Eagle Pharmaceuticals (NASDAQ:EGRX) is likely to report quarterly earnings at $1.06 per share on revenue of $62.60 million. • 2sevent
Aytu BioPharma (NASDAQ:AYTU) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here's what investors need to know before the announcement. Analysts estimate that Aytu BioPharma will report an earnings per share (EPS) of $-0.04. Aytu BioPharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.36, which was followed by a 39.06% increase in th
Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to [email protected]'s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.If attendees are not able to
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions."On behalf of the entire company, I am delighted to welcome Mark to Aytu and look forward to partnering with him as we
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -- Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET -ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commerciali
ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the appointment of Richard Eisenstadt as Chief Financial Officer. Mr. Eisenstadt is an accomplished pharmaceutical industry executive with more than 20 years of experience in leading finance and accounting operations, supporting clinical development and commercialization, and raising capital within the life sciences sector. Mr. Eisenstadt replaces David Green who has stepped down as Chief Financial Officer as of March 31, 2021. Mr. Eisenstadt most recently was Chief Financial Offic
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4 millionTTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business$19.8 million cash balance at March 31, 2024Company to host conference call and webcast today, May 15, 2024, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / May 15, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, May 15, 2024, at 4:30 p.m. Eastern TimeCall-in Information: Interested parties can access the conference call by di
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 millionQ2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023$19.5 million cash balance at December 31, 2023Company to host conference call and webcast today, February 14, 2024 at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / February 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.Q2 2024 High
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, February 14, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer section.Conference Call DetailsDate and Time: Wednesday, February 14, 2024, at 4:30 p.m. Eastern timeCall-in Information: Interested parties can access t
Q1 2024 Adjusted EBITDA of $2.2 millionRx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024Q1 2024 ADHD net revenue up 31% compared to Q1 2023$20.0 million cash balance at September 30, 2023Company to host conference call today at 4:30pm ETDENVER, CO / ACCESSWIRE / November 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the first quarter of fiscal 2024 ended September 30, 2023.Q1 2024 Commercial Highlights (3 months ending September 30, 2023)Total net revenue was $22.1 million, compared to $27.7 million. The ch
DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after the market close on Tuesday, November 14, 2023. The Company has scheduled a conference call that same day, Tuesday, November 14, 2023, at 4:30 pm ET, to review the results.Conference Call InformationDate and Time: Tuesday, November 14, 2023, at 4:30 pm ETCall-in Information: Interested parties can access the conference call by dialing (888) 506-0062 or (973) 528-0011 using the participant access code
Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 millionRecord Q4 2023 total prescriptions increased 32% compared to Q4 2022Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million in Q4 2023Company to host conference call today at 4:30pm ETENGLEWOOD, CO / ACCESSWIRE / September 27, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fourth quarter and fiscal year ended June 30, 2023.Q4 2023 Commercial Highlights (3 months ending June 30, 2023)Total net revenue was $30.7 million, an increase of 12% from the $27.4 mill
ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close on Wednesday, September 27, 2023. The Company has scheduled a conference call that same day, Wednesday, September 27, 2023, at 4:30 pm ET, to review the results.Conference Call InformationDate and Time: Wednesday, September 27, 2023, at 4:30 pm ETCall-in Information: Interested parties can access the conference call by dialing (888) 506-0062 or (973) 528-0011 using the participant access code 381283.We
Total prescriptions increased 32% compared to Q3 2022 to highest level in Company historyCompany to host conference call today at 4:30pm ETENGLEWOOD, CO / ACCESSWIRE / May 11, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended March 31, 2023.Q3 2023 Commercial Highlights (3 months ending March 31, 2023)Total net revenue was $22.7 million, a decrease of 6% from the $24.2 million in net revenue in the year-ago quarter. Revenue during Q3 2023 was impacted
ENGLEWOOD, CO / ACCESSWIRE / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its third quarter fiscal year 2023, ended March 31, 2023, after the market close on Thursday, May 11, 2023. The Company has scheduled a conference call that same day, Thursday, May 11, 2023, at 4:30 pm ET, to review the results.Conference Call InformationDate and Time: Thursday, May 11, 2023, at 4:30 pm ETCall-in Information: Interested parties can access the conference call by dialing (888) 506-0062 or (
DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024.WebcastThe webcasted fireside chat will take place at 12:15 p.m. Eastern time on Thursday, August 15, 2024. The webcast can be accessed by visiting the investor relations section of the Company's website at https://investors.aytubio.com or direct
Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx SegmentEliminates Materially All Remaining Expenses Associated with the Consumer Health BusinessProvides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / ACCESSWIRE / August 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that following the wind down of operations, it has entered into a definitive agreement to divest its Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company. The divested business encompasses the established e-commerce pl
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485
MIAMI, July 16, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteMedi
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debtInterest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loanTerm loan maturity extended to June 12, 2028Extension of Revolving Credit Facility increases potential borrowing capacityDENVER, CO / ACCESSWIRE / June 18, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.WebcastThe webcasted fireside chat will take place at 1:15pm ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or directly at https://wsw.com/webcast/lytham11/aytu/2126355. The webcast will also be availab
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4 millionTTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business$19.8 million cash balance at March 31, 2024Company to host conference call and webcast today, May 15, 2024, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / May 15, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, May 15, 2024, at 4:30 p.m. Eastern TimeCall-in Information: Interested parties can access the conference call by di
Webcasted presentation to take place at 4:40 p.m. Eastern timeDENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.Mr. Disbrow will present on Thursday, April 4, 2024, at 4:40 p.m. Eastern time. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE.During the event, Mr. Disbrow will update participants on Aytu's commercial progress made since his last presentation to participants at the Emerging Growth Conf
MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 2April 4, 2024 10:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to
SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13G - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13D - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13G - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)